Axena Health Begins First-of-Its-Kind Global Study of Female Incontinence

Axena Health, Inc. (Axena Health), a women’s health medical device company focused on scalable treatments for female pelvic health, announced today a large-scale study that will investigate the burdens of incontinence on women in low- and middle-income countries to support equitable access to treatment. The first-of-its-kind study will examine how women could access treatment within local healthcare delivery systems and in a manner that accommodates cultural norms. Study results will be available in late 2023 and will inform the development of new treatment options based on the Leva^® Pelvic Health System, a digital health treatment for urinary incontinence (UI) with published studies supporting its effectiveness, including durable, long-term symptom relief. Read more.

Source: Yahoo! Finance, May 19, 2023

TENA Launches Lights Sensitive Ultra Pads Tackling a Lesser-Known Menopause Symptom

TENA, the UKs leading incontinence brand for over 60 years, has launched a new range of Lights Sensitive Ultra Pads, designed to manage bladder leaks and support healthy intimate skin. This latest product innovation features a unique skin caring emulsion that has been specifically designed for sensitive skin by helping to limit friction, making it the first of its kind to the UK market. Continuing in its mission to better support women during the menopause, the introduction of the TENA Lights Sensitive Ultra will help the large number of women who suffer with skin irritation and incontinence – two of the many lesser-known menopausal symptoms. Read more.

Source: Retail Times, November 19, 2022

BioDerm, Inc. Begins Distribution in Home Care Markets of a New Revolutionary Female Incontinence Device From TillaCare, Ltd

BioDerm is excited to partner with TillaCare as a U.S. distributor of TillaCare’s UriCap Female. UriCap Female is a revolutionary external urine collection system offering female patients with urinary incontinence a comfortable, easy-to-use solution without the skin irritation and discomfort associated with absorbent products. Following the successful launch of UriCap Female in hospital and institutional settings, BioDerm launched a direct-to-consumer campaign allowing patients to receive UriCap Female for in-home use. Read more.

Source: Index-Journal, October 28, 2022

Viveca Biomed Launches Contrelle To Create ‘Revolution’ In Tackling Stress Urinary Incontinence

Viveca Biomed has launched an innovative and clinically-proven bladder support device, Contrelle that offers women immediate relief from stress urinary incontinence (SUI) and provides community pharmacy contractors with a way to build a new consumer base, customer loyalty and sales margins. The product, named ‘Contrelle Activgard’, has already recorded millions of sales in Scandinavia over a decade. Read more.

Source: Pharmacy Business, August 24, 2022

First Quality Introduces MaxSorb+ Zone For Bladder Control Pads

First Quality Products, Inc. is launching a new technology for bladder control pads called MaxSorb+ Zone, providing enhanced rapid absorption to help keep skin dry all day and support skin health. Pads that use First Quality’s MaxSorb+ Zone absorb up to 50% faster compared to previous Prevail bladder control pads. Read more.

Source: Nonwovens Industry, April 28, 2022

First Patients Enrolled in Uromedica’s Adjustable Continence Therapy (ACT®) for Female Stress Urinary Incontinence (SUI) Trial

Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI. Stress urinary incontinence is the accidental leakage of urine that can occur when sneezing, coughing, or performing physical activity. The investigational intent of the ACT trial, a post-operatively adjustable, minimally invasive outpatient procedure, is to assess safety and efficacy for women who suffer from moderate or severe SUI. Read more.

Source: Business Wire, March 10, 2021

FDA Grants DeNovo Clearance to Atlantic Therapeutics for INNOVO® Therapy Device to Treat Stress Urinary Incontinence

Atlantic Therapeutics, a global manufacturer of innovative, garment-based pelvic floor muscle strengthening and nerve stimulation products, announced today (13.11.18) that the U.S. Food and Drug Administration (FDA) has granted a DeNovo clearance for its INNOVO^® therapy device, an externally worn electrical muscle stimulator for the treatment of stress urinary incontinence in adult females. INNOVO^® is the first transcutaneous electrical stimulation continence device to be cleared by the FDA, following results of two randomized controlled trials (RCTs) demonstrating it to be an effective and low-risk device for the treatment for stress urinary incontinence (SUI) in adult females. Read more.

Source: Business Wire, November 13, 2018

Renovia Launches “REDUCE” – a Multi-Center Randomized Controlled Trial to Study Next-Generation leva® Pelvic Digital Therapeutic System for Urinary Incontinence

Renovia Inc. (“Renovia”), a company dedicated to discovering and delivering first-line digital therapeutic and diagnostic devices for women with pelvic floor disorders, today announced it has launched a large, multi-center randomized controlled trial (RCT) to study the efficacy of a first-line non-surgical digital therapeutic for the treatment of stress-dominant urinary incontinence (UI). Pelvic floor muscle exercises (PFME), also known as Kegel exercises, are the widely accepted first-line conservative treatment for pelvic floor disorders including stress, urgency, and mixed UI within the urogynecology, urology and physical therapy communities. However, many women have trouble identifying and contracting the correct muscles when performing these exercises, and remembering to perform the exercises regularly can be challenging. Read more.

Source: Business Wire, November 12, 2018

Nearly Half of Women Over 50 Experience Incontinence, but Most Haven’t Talked to a Doctor

Nearly half of women over 50 say they sometimes leak urine — a problem that can range from a minor nuisance to a major issue — according to a new national poll. Of more than 1,000 women between the ages of 50 and 80 who answered the poll, 43 percent of women in their 50s and early 60s said they had experienced urinary incontinence, as had 51 percent of those age 65 and over. Yet two-thirds of these women hadn’t talked to a doctor about the sometimes embarrassing, little-discussed issue. And only 38 percent said they do exercises that can strengthen the muscles that can help keep urine in. The poll shows they’re finding ways of coping on their own – from using pads or special underwear to wearing dark clothing and limiting fluid intake. Read more.

Source: MHealth Lab, OCtober 31, 2018

Nearly 1 in 2 Women Aged 45+ Report Urinary Incontinence

Urinary incontinence occurs in nearly 1 in 2 women aged 45 years and older, a new study suggests. The study examined survey results from 143,096 women at baseline (2006–2009) and 59,060 women who participated in a follow-up survey (2012–2015). The prevalence of urinary leakage reported in these surveys was 44% and 44.6%, respectively, Kristine Concepcion, MD, MPH, of Family Planning NSW Ashfield in New South Wales, Australia, and colleagues reported in Neurourology and Urodynamics. Read more.

Source: Renal and Urology News, August 2, 2018